|XDATA – January 4th 2016|
|Atterocor disclosed selling 67% of its $70.7 million brokered equity offering to twenty-one investors. The sale started on December 18th according to the document filed at the SEC. $23.01 million in additional funding can be raised before December 2016 based on the placement’s structure. The private placement’s expected net proceeds will amount to $70.2 million excluding $500,000 paid in brokerage fees by the company. Two previous unregistered financing rounds raised an estimated $17.13 million.|
|The company is focused on the accelerated development of a novel treatment for adrenal cancer, a rare endocrine cancer. Investors include Osage Partners, Frazier Healthcare and 5AM Ventures, The Regents of the University of Michigan through its “MINTS” program, and The Michigan Pre-Seed Capital Fund.|
|The company, headquartered in Ann Arbor MI, is led by Julia C Owens (President and CEO). Atterocor elected to keep its revenues undisclosed.
The board of directors includes Carol Gallagher, James Topper, Randall Whitcomb and William Harrington.
The company has raised an estimated total of $64.83 million via private unregistered security offerings.
Status: First close
Amount offered: $70.7 million
Amount placed: $47.7 million
SEC filing: Source
First sale: 12-18-2015
Data as of: 01-04-2016